IND Safety Analysis Requires Broader Unblinding Of Reports, US FDA Advises
This article was originally published in SRA
Executive Summary
A draft guidance from the US Food and Drug Administration is recommending that pharmaceutical sponsors develop safety assessment committees that would review safety information in a drug development program and determine what information must be reported in an investigational new drug (IND) safety report.